Dr. Joseph Kozikowski will present and chair an industry panel discussion on value-driven strategy for building and managing product portfolios of specialty pharmaceuticals.
FRAMINGHAM, MA – October 5, 2002 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. will chair an industry panel discussion and present an industry sector equity valuation analysis on specialty pharma at the CBI Specialty Pharma Conference.
Dr. Kozikowski will share his perspectives in a presentation entitled “The Franchise Gilded Cage: Does Constraining the Specialty Pharma Portfolio Create Enterprise Value?” on October 8, 2002 in Philadelphia, PA.
In his presentation Dr. Kozikowski will explore and evaluate the hypothesis that constraining a specialty pharmaceutical product portfolio to several therapeutic areas which share common core competency requirements may create more enterprise value than simply commercializing an aggregation of specialty pharmaceutical products.
In his analysis Dr. Kozikowski defined comparative cohorts of US-listed companies that either constrained their portfolios to several therapeutic areas, or that did not. He then evaluated near-term and intermediate term share price performance, price-to-earnings, sales, and earnings growth multiples realized, free cash flow indices of value creation, and various balance sheet indices of value creation.
His results demonstrate that constraining the product portfolio to therapeutic areas aligned with core competencies tends to create significantly more value than simply commercializing aggregations of specialty pharmaceutical products.